Trial Profile
Double-Blind, Randomized, Single Dose Escalation Safety Study of Intraarticular Bone Morphogenic Protein (38A BMP-7) in Subjects With Osteoarthritis (OA) of the Knee
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Eptotermin alfa (Primary)
- Indications Osteoarthritis
- Focus Adverse reactions
- Sponsors Stryker Corporation
- 23 Oct 2014 New trial record